Abstract:Objective: To understand the role of urotensin Ⅱ ( U Ⅱ ) and proadrenomedullin N-terminal 20 peptide ( PAMP) , a fragment of proadrenomedullin ( proADM ) possessing biological activity, in the pathophysiological process of congestive heart failure (CHF) by observing the variation of their plasma levels and exploring their interrelations. Methods: Plasma U Ⅱ and PAMP levels were measured by radioimmunoassay in 52 patients with CHF and 14 healthy subjects. Left ventricular ejection fraction (LVEF) and the ratio of E/A were determined by echocardiography. Results: The plasma U Ⅱ level was significantly lower in patients with CHF than the healthy subjects (1.5±1.0 pg/ml vs 4. 3±1.2 pg/ml, P 0.05), while plasma PAMP level was significantly higher in the former group (30. 6±5. 8 pg/ml vs 21.0±6.6 pg/ml P 0. 05 ). The levels of U Ⅱ and PAMP were parallel with the severity of CHF, and significant correlation of plasma levels of U Ⅱ with LVEF (r=0.530, P=0.000) and the ratio of E/A (r=0.618, P = 0. 000) was noted. LVEF and ratio of E/A were found to be inversely correlated with plasma PAMP levels in the patients ( r = - 0. 568, P = 0. 000; r = - 0. 350, P ?0. 004 ) . Also found was the significant correlation between plasma U Ⅱ and PAMP levels (r= -0.528, P = 0. 000) . The treatment of the patients resulted in increased plasma U Ⅱ levels and lowered PAMP levels. Conclusion: The variations of plasma levels of U Ⅱ and PAMP are parallel with the severity of CHF, suggesting their cooperative actions in the pathophysiology of CHF.

Relationship of the Plasma Urotensin Ⅱ with Proadrenomedullin N-terminal 20 Peptide in Patients with Congestive Heart Failure